All In Biotech

Drug Trial Radar · NCT06529419

A Dose Range-Finding Study to Assess the Efficacy and Safety of Multiple Dose Levels of AZD8630 in Adults With Uncontrolled Asthma at Risk of Exacerbations

A Phase 2b, Randomised, Double-Blind, Placebo-Controlled Dose Range-Finding Study to Assess Efficacy and Safety of Multiple Dose Levels of Inhaled AZD8630 Given Once Daily for 12 Weeks in Adults With Uncontrolled Asthma at Risk of Exacerbations (LEVANTE)

Last checked: Nov 19, 2026Latest source record: Mar 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 537 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

537

Actual

Start

Aug 30, 2024

Primary completion

Feb 4, 2026

Study completion Feb 4, 2026

Sponsor

Lead sponsor
AstraZenecaAstraZeneca (AZN)
Sponsor type
Industry
First posted
Jul 31, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A dose range-finding study to assess the efficacy and safety of multiple dose levels of AZD8630 administered via a dry powder inhaler in adults with uncontrolled asthma at risk of exacerbations, receiving medium -to -high dose inhaled corticosteroid (ICS)/long-acting β2-agonist (LABA).

Conditions

  • Asthma

Interventions

  • AZD8630Drug

    The drug will be administered by inhalation

  • PlaceboDrug

    The placebo will be administered by inhalation

  • InhalerDevice

    The drug/placebo will be administered by inhalation using the inhaler

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Time to first CompEx Asthma eventTime frame: 12 weeks

Locations

196 sites in 23 countries. Site status is shown where the registry gives one.

  • Research Site

    Mesa, Arizona

  • Research Site

    Huntington Beach, California

  • Research Site

    La Mesa, California

  • Research Site

    Laguna Niguel, California

  • Research Site

    Lancaster, California

  • Research Site

    Long Beach, California

  • Research Site

    San Jose, California

  • Research Site

    New Haven, Connecticut

  • Research Site

    DeBary, Florida

  • Research Site

    Jacksonville, Florida

  • Research Site

    Jensen Beach, Florida

  • Research Site

    Largo, Florida

  • Research Site

    Miami, Florida

  • Research Site

    Miami Lakes, Florida

  • Research Site

    Tampa, Florida

  • Research Site

    Lilburn, Georgia

  • Research Site

    Savannah, Georgia

  • Research Site

    Chicago, Illinois

  • Research Site

    Winfield, Illinois

  • Research Site

    Ames, Iowa

  • Research Site

    Kansas City, Kansas

  • Research Site

    Baltimore, Maryland

  • Research Site

    Methuen, Massachusetts

  • Research Site

    Ann Arbor, Michigan

  • Research Site

    Detroit, Michigan

  • Research Site

    Las Vegas, Nevada

  • Research Site

    Las Vegas, Nevada

  • Research Site

    Riverdale, New Jersey

  • Research Site

    Middletown, New York

  • Research Site

    Greenville, North Carolina

  • Research Site

    Winston-Salem, North Carolina

  • Research Site

    Beavercreek, Ohio

  • Research Site

    Lima, Ohio

  • Research Site

    Oklahoma City, Oklahoma

  • Research Site

    Horsham, Pennsylvania

  • Research Site

    Austin, Texas

  • Research Site

    McKinney, Texas

  • Research Site

    Mesquite, Texas

  • Research Site

    Pearland, Texas

  • Research Site

    San Antonio, Texas

Showing 40 of 196 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.